‘Living’ guideline advises GPs on use of GLP-1 and SGLT-2 drugs in type 2 diabetes

A rapid evolving guideline has recommended two key drugs be prescribed in all patients with type 2 diabetes who are at higher risk of cardiovascular and kidney complications. Alongside those at most high risk, SGLT-2 inhibitor and GLP-1 receptor agonist drugs should also be prescribed to ‘most’ adults with type 2 diabetes who fall into The post ‘Living’ guideline advises GPs on use of GLP-1 and SGLT-2 drugs in type 2 diabetes appeared first on Pulse Today.